|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2002-6-27
|
|
pubmed:abstractText |
STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies is explored.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1535-6108
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
31-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12086885-Animals,
pubmed-meshheading:12086885-Antineoplastic Agents,
pubmed-meshheading:12086885-Binding Sites,
pubmed-meshheading:12086885-Clinical Trials as Topic,
pubmed-meshheading:12086885-Drug Delivery Systems,
pubmed-meshheading:12086885-Drug Resistance, Neoplasm,
pubmed-meshheading:12086885-Enzyme Inhibitors,
pubmed-meshheading:12086885-Fusion Proteins, bcr-abl,
pubmed-meshheading:12086885-Humans,
pubmed-meshheading:12086885-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:12086885-Piperazines,
pubmed-meshheading:12086885-Protein Binding,
pubmed-meshheading:12086885-Protein Conformation,
pubmed-meshheading:12086885-Protein Structure, Tertiary,
pubmed-meshheading:12086885-Protein-Tyrosine Kinases,
pubmed-meshheading:12086885-Pyrimidines
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Perspectives on the development of a molecularly targeted agent.
|
|
pubmed:affiliation |
Leukemia Center, Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Road, Portland 97201, USA. drukerb@ohsu.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Review,
Research Support, Non-U.S. Gov't
|
